Article Versions Notes

Feijtel D, Reuvers TGA, van Tuyll-van Serooskerken C, de Ridder CMA, Stuurman DC, de Blois E, Verkaik NS, de Bruijn P, Koolen SLW, de Jong M, et al. In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib. Cancers. 2023; 15(3):915. https://doi.org/10.3390/cancers15030915

Feijtel, Danny, Thom G. A. Reuvers, Christine van Tuyll-van Serooskerken, Corrina M. A. de Ridder, Debra C. Stuurman, Erik de Blois, Nicole S. Verkaik, Peter de Bruijn, Stijn L. W. Koolen, Marion de Jong, and et al. 2023. "In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib" Cancers 15, no. 3: 915. https://doi.org/10.3390/cancers15030915

Feijtel, D., Reuvers, T. G. A., van Tuyll-van Serooskerken, C., de Ridder, C. M. A., Stuurman, D. C., de Blois, E., Verkaik, N. S., de Bruijn, P., Koolen, S. L. W., de Jong, M., & Nonnekens, J. (2023). In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib. Cancers, 15(3), 915. https://doi.org/10.3390/cancers15030915